Briefing

Featured article

Sanofi’s $17bn sale of Opella to US investors advances following government deal

Also in this section

News in Numbers

Latest News

Latest Deals

Project Updates

11/20/2024 11:10:16
  • Home | Pharma's green shift with dry powder inhalers
  • Editor's letter
  • Contents
  • Mimotopes Company Insight
  • Mimotopes
  • Briefing
  • News in Numbers
  • Latest News
  • Latest Deals
  • Project Updates
  • Alphial - CPHI
  • Syngene Company Insight
  • In Depth
  • Pharma's green shift: dry powder inhalers promise lower emissions
  • Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
  • What is the pharmacy of the future?
  • Obesity trial surge puts the focus back on decentralisation
  • A slow start for self-amplifying mRNA vaccines
  • For pharma companies, the possibilities of green chemistry are huge
  • Will the tide turn for the wave of pharma layoffs?
  • Investment and Development Agency of Latvia Company Insight
  • AlfatestLAB - CPHI
  • Sponsored Supplements
  • RHEACELL Company Insight
  • Listings
  • Events
  • Excellence Awards
  • Innovation Rankings
  • Buyer's Guides
  • Next issue
11/20/2024 00:00:00